Missouri is currently home to 1892 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Saint Louis, Kansas City, St. Louis and Springfield. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
TEMPUS ARIES: A Biobank Registry Platform Study in Oncology
NCT06207032
Recruiting
This study is a non-interventional, multicenter, multicohort evaluation of participants with cancer who will undergo longitudinal plasma ctDNA biomarker profiling at specific time points in addition to standard of care therapy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
05/05/2025
Locations: Hannibal Regional Healthcare System, Inc., Hannibal, Missouri
Conditions: Cancer
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
05/05/2025
Locations: St. Charles Clinical Research, Saint Louis, Missouri
Conditions: Ulcerative Colitis
Register for Updates
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
NCT05948943
Recruiting
The main purpose of this study in participants with PIK3CA-mutated LyM is to assess the change in radiological response and symptom severity upon treatment with alpelisib film-coated tablets (FCT) as compared to placebo.
Gender:
ALL
Ages:
Between 0 years and 100 years
Trial Updated:
05/05/2025
Locations: WA Uni School Of Med, Saint Louis, Missouri
Conditions: Lymphatic Malformations
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Washington University in St. Louis, Saint Louis, Missouri
Conditions: Severe Aplastic Anemia
Register for Updates
Tempus CRC Surveillance Study: A ctDNA Biomarker Profiling Study of Patients With CRC Using NGS Assays
NCT05234177
Recruiting
The study is an observational multicenter evaluation of participants with colorectal cancer (CRC) who will receive longitudinal plasma ctDNA biomarker profiling in addition to their standard-of-care therapy and disease surveillance.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Mercy Clinic Oncology and Hematology - Joplin, Joplin, Missouri
Conditions: Colorectal Cancer
Register for Updates
VItamin C in Thermal injuRY: The VICToRY Trial
NCT04138394
Recruiting
This study aims to show that giving high dose, intravenous vitamin C in addition to standard care to burned critically ill patients will be associated with less organ dysfunction, improved survival and a quicker rate of recovery. In this study, all patients will receive standard care and of the patients will also receive high dose intravenous vitamin C, while the other half of patients will receive placebo.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Mercy Hospital St. Louis, Saint Louis, Missouri
Conditions: Shock, Thermal Burn
Register for Updates
Post Approval Study (PAS) of the OPTIMIZER Smart and CCM Therapy
NCT03970343
Recruiting
The OPTIMIZER Smart Post-Approval Study is a prospective, multi-center, non-randomized, single arm open label study of 620 subjects receiving an OPTIMIZER implant as standard of care. Patients to be included will have NYHA functional class III symptoms and a left ventricular ejection fraction of 25-45%
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: St. Louis Heart and Vascular, Bridgeton, Missouri
Conditions: Heart Failure
Register for Updates
COOL-IT-PRO: Cryoablation of Breast Cancer in Non-surgical Patients
NCT05972343
Recruiting
This is a subject registry study of patients who undergo cryoablation for their breast cancer after being determined not to be surgical candidates. Data collected as part of this registry will be used to assess the safety of percutaneous ultrasound-guided cryoablation in this population as well as provide long-term follow-up of subjects who received cryoablation.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Breast Cancer, Cancer of the Breast
Register for Updates
Memory-Like Natural Killer Cells With Nivolumab and Relatlimab in Advanced or Metastatic Melanoma After Progression on Checkpoint Inhibitors
NCT05629546
Recruiting
This is a Phase 1 open-label, study designed to characterize the safety, tolerability, and preliminary anti-tumor activity of memory-like natural killer cells (ML NK) in combination with nivolumab and relatlimab in subjects with advanced and/or metastatic melanoma. There will be two arms to test the variables of ML NK cell source. ML NK cells from an autologous source will be used for Arm 1, and ML NK cells from an allogeneic source will be used for Arm 2. The investigators hypothesize that ML N... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/03/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Advanced Melanoma, Metastatic Melanoma
Register for Updates
Implement and Test Visual Consent Template and Process
NCT06804837
Recruiting
The investigators plan to conduct a stepped wedge randomized control trial to implement and test the consent template and process in three studies. Randomization will occur at the research coordinator/research team level. Each participating research team member will begin in the standard consent arm of the study. Subsequently, they will be randomized to the visual key information page arm at staggered time points to undergo training and begin using the visual key information page with patients w... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Cancer, Alzheimer Disease
Register for Updates
Improving Cancer Prevention and Control Through Academic-local Public Health Department Partnerships
NCT06605196
Recruiting
The purpose of this study is to understand how to leverage structures and processes of academic health department (AHD) partnerships to facilitate implementation of cancer related evidence-based programs and policies (EBPPs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Prevention Research Center at Washington University in St. Louis, Saint Louis, Missouri
Conditions: Cancer
Register for Updates
Obeticholic Acid for Prevention in Barrett's Esophagus
NCT04939051
Recruiting
This phase II trial studies the effect of obeticholic acid in treating patients with Barrett's esophagus. Bile acids present in duodenogastroesophageal reflux contribute to neoplastic progression in Barrett's esophagus. Obeticholic acid has shown anti-cholestatic, anti-inflammatory and anti-fibrotic effects mediated by FXR activation. It down regulates bile acid availability and decreases proinflammatory cytokine production including IL-1beta and TNFalpha in human enterocytes and immune cells. T... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/02/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: Barrett Esophagus, Esophageal Adenocarcinoma
Register for Updates